Dermata Therapeutics (DRMA) Accumulated Expenses (2021 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Accumulated Expenses of $734318.0 for Q1 2026, down 23.65% year-over-year from $961759.0 in Q1 2025, and down 25.03% quarter-over-quarter from $979453.0 in Q4 2025.
Dermata Therapeutics (DRMA) Accumulated Expenses (2021 - 2026) Analysis & Trends
Dermata Therapeutics' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $734318.0 for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 23.65% year-over-year to $734318.0; the TTM figure through Mar 2026 stood at $734318.0 (down 23.65% YoY), while the FY2025 annual figure was $979453.0, down 15.91% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $734318.0, down from $979453.0 in the prior quarter.
- The five-year high for Accumulated Expenses was $1.2 million in Q4 2024, with the low at $131257.0 in Q1 2023.
- The 5-year median for Accumulated Expenses is $592695.0 (2024), against an average of $640995.7.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 318.43% in 2024, then tumbled 45.11% in 2025.
- Dermata Therapeutics' Accumulated Expenses stood at $425932.0 in 2022, then jumped by 77.87% to $757588.0 in 2023, then jumped by 53.75% to $1.2 million in 2024, then dropped by 15.91% to $979453.0 in 2025, then retreated by 25.03% to $734318.0 in 2026.
- Business Quant data shows DRMA's Accumulated Expenses at $734318.0 in Q1 2026, $979453.0 in Q4 2025, and $594144.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 734,318.00 |
| Dec 31, 2025 | 979,453.00 |
| Sep 30, 2025 | 594,144.00 |
| Jun 30, 2025 | 490,703.00 |
| Mar 31, 2025 | 961,759.00 |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 591,246.00 |
| Mar 31, 2024 | 549,220.00 |
| Dec 31, 2023 | 757,588.00 |
| Sep 30, 2023 | 329,049.00 |
| Jun 30, 2023 | 181,967.00 |
| Mar 31, 2023 | 131,257.00 |
| Dec 31, 2022 | 425,932.00 |
| Dec 31, 2021 | 766,207.00 |